LIFE - aTyr Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.61
-0.02 (-3.28%)
At close: 4:00PM EST

0.61 -0.00 (-0.33%)
After hours: 5:16PM EST

Stock chart is not supported by your current browser
Previous Close0.63
Open0.62
Bid0.61 x 900
Ask0.65 x 1400
Day's Range0.60 - 0.65
52 Week Range0.59 - 4.35
Volume966,050
Avg. Volume525,106
Market Cap18.213M
Beta (3Y Monthly)2.60
PE Ratio (TTM)N/A
EPS (TTM)-1.52
Earnings DateNov 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.18
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    aTyr Pharma to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 13, 2018

    SAN DIEGO, Nov. 08, 2018 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire27 days ago

    aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting

    SAN DIEGO, Oct. 17, 2018 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.

  • GlobeNewswire28 days ago

    aTyr Pharma Announces Leadership Transition

    SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the resignation of David J. King, Ph.D. as Chief Scientific Officer of aTyr, effective as of December 31, 2018. Dr. King will be pursuing an opportunity as a founder of a private biotechnology company in a non-competitive area and in biology distinct from aTyr. Through the end of the year, Dr. King will assist in transition activities and recruitment of new leadership to continue aTyr’s research efforts.

  • GlobeNewswire2 months ago

    aTyr Pharma Announces Pulmonary Sarcoidosis as Disease Indication for Phase 1b/2a Clinical Study and Educational Webinar

    SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has selected pulmonary sarcoidosis as the disease indication for its upcoming ATYR1923 clinical study.  In the fourth quarter of 2018, aTyr plans to initiate a Phase 1b/2a multiple-ascending dose, placebo-controlled, first-in-patient study with ATYR1923 for the treatment of patients with pulmonary sarcoidosis.  The study has been designed to evaluate safety, tolerability and immunogenicity of multiple doses of ATYR1923.  In addition, aTyr intends to evaluate established clinical endpoints and potential biomarkers to assess preliminary activity of ATYR1923. From San Antonio, the site of the CHEST Annual Meeting 2018, aTyr will host an educational webinar on Monday, October 8, 2018 at 8:00 a.m. Eastern Time featuring Daniel Culver, D.O., Director of the Interstitial Lung Disease Program at the Cleveland Clinic.  Dr. Culver is also the President-elect of the World Association of Sarcoidosis and Other Granulomatous Disorders and the Chair of the Scientific Advisory Board for the Foundation for Sarcoidosis Research.  During the educational webinar, Dr. Culver will provide disease education on pulmonary sarcoidosis and its impact on patients.

  • GlobeNewswire2 months ago

    aTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

    SAN DIEGO, Sept. 20, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of LIFE earnings conference call or presentation 14-Aug-18 9:00pm GMT

    Q2 2018 aTyr Pharma Inc Earnings Call

  • GlobeNewswire2 months ago

    aTyr Pharma to Present at the Baird 2018 Global Healthcare Conference

    SAN DIEGO, Aug. 30, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay ...

  • Associated Press3 months ago

    Atyr Pharma: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 35 cents. In the final minutes of trading on Tuesday, the company's shares hit 66 cents. A year ago, they were trading at $3.25. ...

  • ACCESSWIRE3 months ago

    aTyr Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 5:00 PM Eastern Time. ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT

    Q4 2017 aTyr Pharma Inc Earnings Call

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of LIFE earnings conference call or presentation 14-May-18 12:00pm GMT

    Q1 2018 aTyr Pharma Inc Earnings Call

  • Associated Press6 months ago

    Atyr Pharma: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 36 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • ACCESSWIRE6 months ago

    aTyr Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 8:00 AM Eastern Time. To listen ...

  • aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?
    Zacks8 months ago

    aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?

    aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?

  • Associated Press8 months ago

    Atyr Pharma reports 4Q loss

    The San Diego-based company said it had a loss of 39 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...